The finding that most pharmacy costs were numerically higher for Gla-300 than for long-acting basal insulin/NPH analogs is similar to that reported in another claims-based analysis, which showed that for people with type 2 diabetes initially receiving long-acting basal insulin/NPH, switching to Gla-300 vs Gla-100 or IDet 100 U/mL was associated with similar total healthcare costs despite higher pharmacy costs.40 Here, INS is linked to type 2 diabetes mellitus.